Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 8.6% – Should You Sell?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)’s stock price traded down 8.6% during mid-day trading on Wednesday . The company traded as low as $30.16 and last traded at $30.16. Approximately 33,490 shares were traded during mid-day trading, a decline of 91% from the average session volume of 382,301 shares. The stock had previously closed at $32.99.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Royal Bank Of Canada initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They issued an “outperform” rating and a $40.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday. Wedbush restated an “outperform” rating and issued a $35.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, June 12th. Finally, Evercore began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.43.

Damora Therapeutics, Inc. Common Stock Stock Performance

The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -5.42 and a beta of 1.46. The stock’s 50 day simple moving average is $25.25 and its 200-day simple moving average is $25.65.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23). On average, analysts expect that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current fiscal year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $40,000. Geode Capital Management LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $266,000. Virtu Financial LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the third quarter worth about $49,000. Sigma Planning Corp acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $334,000. Finally, Two Sigma Investments LP purchased a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter valued at approximately $76,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.